GGrantIndex
← Leaderboards

David S Chia

University Of California Los Angeles

$9,399,833
Attributed
$10,892,480
Total exposure
6
Grants
2
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$10,892,480 · 6

By mechanism

U24$7,307,439 · 1
N01$1,592,919 · 2
UH3$1,158,300 · 1
R21$465,376 · 1
UH2$368,446 · 1

Top collaborators

Most similar at University Of California Los Angeles

Same institution · by research overlap

Others in their field

Top investigators on “Detection

Research focus

DetectionHuman ResourcesLaboratoriesLiquid SubstanceResourcesTissuesMalignant Neoplasm Of LungBiomarkerDiagnosisCostClinical ResearchMemberMolecular ProfilingMissionEarly Detection Research NetworkMalignant Neoplasm Of ProstateNucleic AcidsLeadershipDensityComprehensive Cancer CenterCollaborationsDesignDna Modification ProcessFunding

Grant awards (25)

Saliva Anti-SSA/Ro and Anti-SSB/La for Early Detection of Sjögren’s and SICCA Syndromes$205,001
R21 · FY2025 · DE
Saliva Anti-SSA/Ro and Anti-SSB/La for Early Detection of Sjögren’s and SICCA Syndromes$260,375
R21 · FY2024 · DE
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$390,000
UH3 · FY2021 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$390,000
UH3 · FY2020 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$378,300
UH3 · FY2019 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$184,223
UH2 · FY2018 · CA
Advancing EFIRM-Liquid Biopsy (eLB) to a CLIA-Certified Laboratory Developed Test (eLB-LDT) for Detection of Actionable EGFR Mutations in NSCLC Patients$184,223
UH2 · FY2017 · CA
The Early Detection Research Network Biomarker Resource Laboratory at UCLA$369,494
U24 · FY2014 · CA · contact PI
The Early Detection Research Network Biomarker Resource Laboratory at UCLA$358,065
U24 · FY2013 · CA · contact PI
The Early Detection Research Network Biomarker Resource Laboratory at UCLA$379,129
U24 · FY2012 · CA · contact PI
The Early Detection Research Network Biomarker Resource Laboratory at UCLA$380,921
U24 · FY2011 · CA · contact PI
The Early Detection Research Network Biomarker Resource Laboratory at UCLA$392,700
U24 · FY2010 · CA · contact PI
The Early Detection Research Network: Biomarker Referen*$154,000
U24 · FY2010 · CA · contact PI
The Early Detection Research Network: Biomarker Referen*$459,897
U24 · FY2009 · CA · contact PI
The Early Detection Research Network: Biomarker Referen*$473,491
U24 · FY2008 · CA · contact PI
PROSTATE, LUNG, COLORECTAL, AND OVARIAN (PLCO) CANCER SCREENING TRIAL - LABORA$1,008,581
N01 · FY2007 · CA · contact PI
The Early Detection Research Network: Biomarker Referen*$474,500
U24 · FY2007 · CA · contact PI
The Early Detection Research Network: Biomarker Referen*$133,316
U24 · FY2006 · CA · contact PI
The Early Detection Research Network: Biomarker Referen*$613,916
U24 · FY2005 · CA
BIOMARKERS VALIDATION LABORATORIES$736,236
U24 · FY2004 · CA
BIOMARKERS VALIDATION LABORATORIES$714,899
U24 · FY2003 · CA
BIOMARKERS VALIDATION LABORATORIES$694,835
U24 · FY2002 · CA
BIOMARKERS VALIDATION LABORATORIES$676,070
U24 · FY2001 · CA
PROSTATE, LUNG, COLORECTAL, AND OVARIAN (PLCO) CANCER$584,338
N01 · FY2000 · CN
BIOMARKERS VALIDATION LABORATORIES$295,970
U24 · FY2000 · CA